GlassScriptPhysician profile
Brandon Roses
NPI 1851812044
$8,892.97
in general payments reported to CMS, 2019-2025
46 companies · $2,077 in 2025
The $2,077 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,238 · 2022: $1,632 · 2023: $1,757 · 2024: $2,189 · 2025: $2,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,914 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,914.27 |
| Education | $108.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,897.18 | 2021-2025 | |
| Pfizer INC. | $1,305.36 | 2021-2025 | |
| Novo Nordisk INC | $717.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $545.78 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| E.R. Squibb & Sons, L.L.C. | $528.37 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $483.22 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $415.87 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $331.74 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $206.62 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $204.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.34 | 2022-2025 | Trintellix |
| Abbott Laboratories | $177.04 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $142.67 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $136.81 | 2021-2023 | Qelbree |
| Bausch Health US, LLC | $128.05 | 2021-2023 | Wellbutrin, Aplenzin |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $117.98 | 2024-2025 | Rexulti |
| Amgen INC. | $109.71 | 2022-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $106.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $101.31 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.88 | 2024-2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $88.05 | 2021 | |
| Merck Sharp & Dohme LLC | $66.27 | 2021-2023 | Vaxelis, M-M-R II, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $65.81 | 2025 | Zoryve |
| Acadia Pharmaceuticals INC | $63.59 | 2024-2025 | Daybue |
| Organon LLC | $53.99 | 2023-2025 | Nexplanon |
| Ironshore Pharmaceuticals INC. | $48.71 | 2023 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.79 | 2023-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $42.49 | 2022-2024 | Keveyis |
| Corium, LLC | $40.85 | 2023 | Azstarys |
| Daiichi Sankyo INC. | $39.36 | 2021 | |
| Ascendis Pharma Endocrinology INC | $38.87 | 2025 | Yorvipath |
| Medtronic, INC. | $36.50 | 2022-2024 | Venaseal |
| Esperion Therapeutics, INC. | $34.32 | 2021 | |
| Amarin Pharma, INC. | $33.88 | 2021-2022 | |
| Coala Life INC | $32.79 | 2021 | |
| Lucid Diagnostics INC. | $28.61 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $24.59 | 2025 | |
| Azurity Pharmaceuticals, INC. | $24.00 | 2024 | Horizant |
| Antares Pharma, INC. | $23.64 | 2022 | |
| Therapeuticsmd, INC. | $21.16 | 2021 | |
| Seqirus USA INC | $18.14 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Inspire Medical Systems, INC. | $17.58 | 2025 | Inspire |
| Collegium Pharmaceutical, INC. | $16.10 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $15.65 | 2021 | |
| Dynavax Technologies Corporation | $14.56 | 2021 | |
| Hologic Sales and Service, LLC | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Roses listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.